Middle East Journal of Rehabilitation and Health

Published by: Kowsar

Study of CCR5-59353C/T Polymorphism in the Iranian Patients With Chronic Hepatitis B Virus Infection

Farahnaz Bineshian 1 , Sajjad Jalali 2 and Zohreh Sharifi 2 , *
Authors Information
1 Department of Parasitology & Mycology, Faculty of Medicine, Semnan University of Medical Sciences, Semnan, Iran
2 Blood Transfusion Research Center, High Institute for Research and Education in Transfusion Medicine, Tehran, Iran
Article information
  • Middle East Journal of Rehabilitation and Health: October 2017, 4 (4); e12658
  • Published Online: July 31, 2017
  • Article Type: Research Article
  • Received: May 6, 2017
  • Revised: June 20, 2017
  • Accepted: July 2, 2017
  • DOI: 10.5812/mejrh.12658

To Cite: Bineshian F, Jalali S, Sharifi Z. Study of CCR5-59353C/T Polymorphism in the Iranian Patients With Chronic Hepatitis B Virus Infection, Middle East J Rehabil Health Stud. 2017 ; 4(4):e12658. doi: 10.5812/mejrh.12658.

Copyright © 2017, Middle East Journal of Rehabilitation and Health Studies. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.
1. Background
2. Objectives
3. Methods
4. Results
5. Discussion
  • 1. Alavian SM, Keyvani H, Rezai M, Ashayeri N, Sadeghi HM. Preliminary report of hepatitis B virus genotype prevalence in Iran. World J Gastroenterol. 2006; 12(32): 5211-3[PubMed]
  • 2. Ajuebor MN, Carey JA, Swain MG. CCR5 in T cell-mediated liver diseases: what's going on? J Immunol. 2006; 177(4): 2039-45[PubMed]
  • 3. Wong MM, Fish EN. Chemokines: attractive mediators of the immune response. Semin Immunol. 2003; 15(1): 5-14[PubMed]
  • 4. Hutter G, Neumann M, Nowak D, Kluter H, Hofmann WK. The beneficial effect of the ccr5-delta32 deletion in gvhd. Chemokine function or genecluster coexpression aside hla match? Vox Sang. 2010; 99(1): 495
  • 5. Samson M, Libert F, Doranz BJ, Rucker J, Liesnard C, Farber CM, et al. Resistance to HIV-1 infection in caucasian individuals bearing mutant alleles of the CCR-5 chemokine receptor gene. Nature. 1996; 382(6593): 722-5[DOI][PubMed]
  • 6. Dragic T, Litwin V, Allaway GP, Martin SR, Huang Y, Nagashima KA, et al. HIV-1 entry into CD4+ cells is mediated by the chemokine receptor CC-CKR-5. Nature. 1996; 381(6584): 667-73[DOI][PubMed]
  • 7. McDermott DH, Zimmerman PA, Guignard F, Kleeberger CA, Leitman SF, Murphy PM. CCR5 promoter polymorphism and HIV-1 disease progression. Multicenter AIDS Cohort Study (MACS). Lancet. 1998; 352(9131): 866-70[PubMed]
  • 8. Mummidi S, Ahuja SS, Gonzalez E, Anderson SA, Santiago EN, Stephan KT, et al. Genealogy of the CCR5 locus and chemokine system gene variants associated with altered rates of HIV-1 disease progression. Nat Med. 1998; 4(7): 786-93[PubMed]
  • 9. Berger EA, Murphy PM, Farber JM. Chemokine receptors as HIV-1 coreceptors: roles in viral entry, tropism, and disease. Annu Rev Immunol. 1999; 17: 657-700[DOI][PubMed]
  • 10. Rehermann B, Lau D, Hoofnagle JH, Chisari FV. Cytotoxic T lymphocyte responsiveness after resolution of chronic hepatitis B virus infection. J Clin Invest. 1996; 97(7): 1655-65[DOI][PubMed]
  • 11. Thio CL, Astemborski J, Bashirova A, Mosbruger T, Greer S, Witt MD, et al. Genetic protection against hepatitis B virus conferred by CCR5Delta32: Evidence that CCR5 contributes to viral persistence. J Virol. 2007; 81(2): 441-5[DOI][PubMed]
  • 12. Wu L, Paxton WA, Kassam N, Ruffing N, Rottman JB, Sullivan N, et al. CCR5 levels and expression pattern correlate with infectability by macrophage-tropic HIV-1, in vitro. J Exp Med. 1997; 185(9): 1681-91[PubMed]
  • 13. Paxton WA, Liu R, Kang S, Wu L, Gingeras TR, Landau NR, et al. Reduced HIV-1 infectability of CD4+ lymphocytes from exposed-uninfected individuals: association with low expression of CCR5 and high production of beta-chemokines. Virology. 1998; 244(1): 66-73[DOI][PubMed]
  • 14. Liu R, Zhao X, Gurney TA, Landau NR. Functional analysis of the proximal CCR5 promoter. AIDS Res Hum Retroviruses. 1998; 14(17): 1509-19[DOI][PubMed]
  • 15. Moriuchi H, Moriuchi M, Fauci AS. Cloning and analysis of the promoter region of CCR5, a coreceptor for HIV-1 entry. J Immunol. 1997; 159(11): 5441-9[PubMed]
  • 16. Miller SA, Dykes DD, Polesky HF. A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res. 1988; 16(3): 1215[PubMed]
  • 17. Tang J, Rivers C, Karita E, Costello C, Allen S, Fultz PN, et al. Allelic variants of human beta-chemokine receptor 5 (CCR5) promoter: evolutionary relationships and predictable associations with HIV-1 disease progression. Genes Immun. 1999; 1(1): 20-7[DOI][PubMed]
  • 18. Clegg AO, Ashton LJ, Biti RA, Badhwar P, Williamson P, Kaldor JM, et al. CCR5 promoter polymorphisms, CCR5 59029A and CCR5 59353C, are under represented in HIV-1-infected long-term non-progressors. The Australian Long-Term Non-Progressor Study Group. AIDS. 2000; 14(2): 103-8[PubMed]
  • 19. Jang DH, Choi BS, Kim SS. The effects of RANTES/CCR5 promoter polymorphisms on HIV disease progression in HIV-infected Koreans. Int J Immunogenet. 2008; 35(2): 101-5[DOI][PubMed]
  • 20. Al-Sharif FM, Al-Jiffii O, Azhar EI. Ccr5 a32 and ccr5-59029 allele frequency among hepatitis c virus infected and in non-hcv infected saudi population. World Appl Sci J. 2011; 13(3): 611-4
  • 21. Ahn SH, Kim DY, Chang HY, Hong SP, Shin JS, Kim YS, et al. Association of genetic variations in CCR5 and its ligand, RANTES with clearance of hepatitis B virus in Korea. J Med Virol. 2006; 78(12): 1564-71[DOI][PubMed]
  • 22. Arababadi MK, Pourfathollah AA, Jafarzadeh A, Hassanshahi G. Decreased expression of CCR5 on the NK cells in occult HBV infected patients. Lab Med. 2010; 41(12): 735-8
  • 23. Kaur G, Singh P, Rapthap CC, Kumar N, Vajpayee M, Sharma SK, et al. Polymorphism in the CCR5 gene promoter and HIV-1 infection in North Indians. Hum Immunol. 2007; 68(5): 454-61[DOI][PubMed]
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:



Create Citiation Alert
via Google Reader

Readers' Comments